NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

NRx Pharmaceuticals (NASDAQ:NRXP) had its price target raised by equities researchers at Ascendiant Capital Markets from $44.00 to $45.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the company. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, November 25th.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $1.26 on Monday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $7.33. The business has a fifty day moving average of $1.35 and a 200 day moving average of $2.08.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.